Show simple item record

dc.contributor.authorTirronen, Annakaisa
dc.contributor.authorHokkanen, Krista
dc.contributor.authorVuorio, Taina
dc.contributor.authorYlä-Herttuala, Seppo
dc.date.accessioned2019-10-31T13:38:58Z
dc.date.available2019-10-31T13:38:58Z
dc.date.issued2019
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/7808
dc.description.abstractThe prevalence of lipid disorders is alarmingly increasing in the Western world. They are the result of either primary causes, such as unhealthy lifestyle choices or inherited risk factors, or secondary causes like other diseases or medication. Atypical changes in the synthesis, processing and catabolism of lipoprotein particles may lead to severe hypercholesterolemia, hypertriglyceridemia or elevated Lp(a). Although cholesterol-lowering drugs are the most prescribed medications, not all patients achieve guideline recommended cholesterol levels with the current treatment options, emphasising the need for new therapies. Also, some lipid disorders do not have any treatment options but rely only on stringent dietary restriction. Patients with untreated lipid disorders carry a severe risk of cardiovascular disease, diabetes, non-alcoholic fatty liver disease and pancreatitis among others. To achieve better treatment outcome, novel selective gene expression and epigenetic targeting therapies are constantly being developed. Therapeutic innovations employing targeted RNA technology utilise small interfering RNAs, antisense oligonucleotides, long non-coding RNAs and microRNAs to regulate target protein production whereas viral gene therapy provides functional therapeutic genes and CRISPR/Cas technology relies on gene editing and transcriptional regulation. In this review, we will discuss the latest advances in clinical trials for novel lipid-lowering therapies and potential new targets in pre-clinical phase.
dc.language.isoenglanti
dc.publisherOxford University Press (OUP)
dc.relation.ispartofseriesHuman molecular genetics
dc.relation.urihttp://dx.doi.org/10.1093/hmg/ddz132
dc.rightsAll rights reserved
dc.subjectpancreatitis
dc.subjecthypercholesterolemia
dc.subjectlipoproteins
dc.subjecthypertriglyceridemia
dc.subjectcardiovascular disease risk factors
dc.subjectgene therapy
dc.subjectgene expression
dc.subjectantisense oligonucleotides
dc.subjectdiabetes mellitus
dc.subjecttype 2
dc.subjectdiet
dc.subjectanticholesteremic agents
dc.subjectgenes
dc.subjectviral
dc.subjectlife style
dc.subjectwestern world
dc.subjectcholesterol measurement test
dc.subjecttreatment outcome
dc.subjectlipid-lowering therapy
dc.subjectlipid disorders
dc.subjectrna
dc.subjectnon-alcoholic fatty liver disease
dc.subjecttranscriptional control
dc.subjectepigenetics
dc.subjectmicrornas
dc.subjectcatabolism
dc.subjectcrispr
dc.subjectgene editing
dc.titleRecent advances in novel therapies for lipid disorders
dc.description.versionfinal draft
dc.contributor.departmentA.I. Virtanen -instituutti
uef.solecris.id63330401en
dc.type.publicationTieteelliset aikakauslehtiartikkelit
dc.rights.accessrights© Authors
dc.relation.doi10.1093/hmg/ddz132
dc.description.reviewstatuspeerReviewed
dc.format.pagerangeR49-R54
dc.relation.issn0964-6906
dc.relation.issueR1
dc.relation.volume28
dc.rights.accesslevelopenAccess
dc.type.okmA1
uef.solecris.openaccessEi


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record